Pfizer Inc - Asset Resilience Ratio
Pfizer Inc (PFIZ34) has an Asset Resilience Ratio of 5.48% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Pfizer Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Pfizer Inc's Asset Resilience Ratio has changed over time. See PFIZ34 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Pfizer Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PFIZ34 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$0.00 | 0% |
| Short-term Investments | R$11.37 Billion | 5.48% |
| Total Liquid Assets | R$11.37 Billion | 5.48% |
Asset Resilience Insights
- Limited Liquidity: Pfizer Inc maintains only 5.48% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pfizer Inc Industry Peers by Asset Resilience Ratio
Compare Pfizer Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
AstraZeneca PLC
NYSE:AZN |
Drug Manufacturers - General | 0.10% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.48% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
Annual Asset Resilience Ratio for Pfizer Inc (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Pfizer Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 6.53% | R$13.60 Billion ≈ $2.67 Billion |
R$208.16 Billion ≈ $40.84 Billion |
-3.06pp |
| 2024-12-31 | 9.60% | R$20.48 Billion ≈ $4.02 Billion |
R$213.40 Billion ≈ $41.87 Billion |
+3.99pp |
| 2023-12-31 | 5.60% | R$12.69 Billion ≈ $2.49 Billion |
R$226.50 Billion ≈ $44.44 Billion |
-5.92pp |
| 2022-12-31 | 11.53% | R$22.73 Billion ≈ $4.46 Billion |
R$197.21 Billion ≈ $38.70 Billion |
-5.59pp |
| 2021-12-31 | 17.12% | R$31.07 Billion ≈ $6.10 Billion |
R$181.48 Billion ≈ $35.61 Billion |
+9.20pp |
| 2020-12-31 | 7.92% | R$12.22 Billion ≈ $2.40 Billion |
R$154.23 Billion ≈ $30.26 Billion |
+2.84pp |
| 2019-12-31 | 5.09% | R$8.53 Billion ≈ $1.67 Billion |
R$167.59 Billion ≈ $32.88 Billion |
-6.01pp |
| 2018-12-31 | 11.10% | R$17.69 Billion ≈ $3.47 Billion |
R$159.42 Billion ≈ $31.28 Billion |
+0.24pp |
| 2017-12-31 | 10.86% | R$18.65 Billion ≈ $3.66 Billion |
R$171.80 Billion ≈ $33.71 Billion |
+1.97pp |
| 2016-12-31 | 8.89% | R$15.26 Billion ≈ $2.99 Billion |
R$171.62 Billion ≈ $33.67 Billion |
-2.85pp |
| 2015-12-31 | 11.74% | R$19.65 Billion ≈ $3.86 Billion |
R$167.38 Billion ≈ $32.84 Billion |
-7.82pp |
| 2014-12-31 | 19.56% | R$32.78 Billion ≈ $6.43 Billion |
R$167.57 Billion ≈ $32.88 Billion |
-- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevna… Read more